Hwang ES, Hyslop T, Lynch T, Frank E, Pinto D, Basila D, et al. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open. 2019;9:e026797.

Article  PubMed  PubMed Central  Google Scholar 

Amin AL, Wagner JL. Contemporary management of atypical breast lesions identified on percutaneous biopsy: a narrative review. Ann Breast Surg. 2021;5:1–9 (AME Publ Co).

Article  Google Scholar 

Baker JL, Bennett DL, Bonaccio E, Camp MS, Chikarmane S, Conant EF, et al. NCCN Guidelines Version 1.2022 breast cancer screening and diagnosis continue NCCN guidelines panel disclosures [Internet]. 2022 [cited 2023 Mar 17]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf

American Society of Breast Surgeons [Internet]. Consensus guideline on concordance assessment of image-guided breast biopsies and management of borderline or high-risk lesions. 2016 [cited 2020 Apr 26]. p. 1–12. Available from: https://www.breastsurgeons.org/docs/statements/Consensus-Guideline-on-Concordance-Assessment-of-Image-Guided-Breast-Biopsies.pdf

Hartmann LC, Degnim AC, Saten RJ, Dupont WD, Ghosh K. Atypical hyperplasia of the breast—risk assessment and management options. New Eng J Med 2015;372(1):78–89.https://doi.org/10.1056/NEJMsr1407164.

Elmore JG, Longton GM, Carney PA, Geller BM, Onega T, Tosteson ANA, et al. Diagnostic concordance among pathologists interpreting breast biopsy specimens. JAMA. 2015;313:1122.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dano H, Altinay S, Arnould L, Bletard N, Colpaert C, Dedeurwaerdere F, et al. Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. Modern Pathol. 2020;33:354–66 (Springer Nature).

Article  CAS  Google Scholar 

Haagensen CD, Lane N, Lattes R, Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 1978;42:737–69.

Article  CAS  PubMed  Google Scholar 

Lewin AA, Mercado CL. Atypical ductal hyperplasia and lobular neoplasia: update and easing of guidelines. Am J Roentgenol. 2020;214:265–75 (American Roentgen Ray Society).

Article  Google Scholar 

Racz JM, Carter JM, Degnim AC. Lobular neoplasia and atypical ductal hyperplasia on core biopsy: current surgical management recommendations. Ann Surg Oncol. 2017;24:2848–54 (Springer, New York LLC).

Article  PubMed  Google Scholar 

Wen HBrogi E. Lobular Carcinoma in Situ. Surg Pathol Clin. 2018 Mar;11(1):123–45. https://doi.org/10.1016/j.path.2017.09.009.

Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. Long-term Follow-up Stud Cancer. 1985;55:2698–708.

CAS  Google Scholar 

Falomo E, Adejumo C, Carson KA, Harvey S, Mullen L, Myers K. Variability in the management recommendations given for high-risk breast lesions detected on image-guided core needle biopsy at U.S. academic institutions. Curr Probl Diagn Radiol. 2019;48:462–6 (United States).

Article  PubMed  Google Scholar 

Schiaffino S, Calabrese M, Melani EF, Trimboli RM, Cozzi A, Carbonaro LA, et al. Upgrade rate of percutaneously diagnosed pure atypical ductal hyperplasia: systematic review and meta-analysis of 6458 lesions. Radiology. 2020;294:76–86 (Radiological Society of North America Inc.).

Article  PubMed  Google Scholar 

Johnson M, Stanczak B, Winblad OD, Amin AL. Breast MRI assists in decision-making for surgical excision of atypical ductal hyperplasia. Surgery. 2023;173(3):612–8. https://doi.org/10.1016/j.surg.2022.07.036.

Estrada J, Larson KE, Kilgore LJ, Wagner JL, Winblad OD, Balanoff CR, et al. Safety of de-escalation of surgical intervention for atypical ductal hyperplasia on percutaneous biopsy: one size does not fit all. Am J Surg. 2023;225:21–5 (Elsevier Inc.).

Article  PubMed  Google Scholar 

Latronico A, Nicosia L, Faggian A, Abbate F, Penco S, Bozzini A, et al. Atypical ductal hyperplasia: our experience in the management and long term clinical follow-up in 71 patients. Breast. 2018;37:1–5 (Churchill Livingstone).

Article  PubMed  Google Scholar 

Grabenstetter A, Sevilimedu V, Kuba MG, Giri DD, Wen HY, et a. Is surgical excision of focal atypical ductal hyperplasia warranted? Experience at a tertiary care center. Ann Surg Oncol. 2023 Mar 11. https://doi.org/10.1245/s10434-023-13319-4. Online ahead of print.

Polat DS, Schopp JG, Arjmandi F, Porembka J, Sarode V, Farr D, et al. Performance of a clinical and imaging-based multivariate model as decision support tool to help save unnecessary surgeries for high-risk breast lesions. Breast Cancer Res Treat. 2021;185:479–94 (Springer).

Article  PubMed  Google Scholar 

Ben LD, Guo M, Liu C, Warburton R, Dingee CK, Pao JS, et al. Development and prospective validation of a risk calculator that predicts a low risk cohort for atypical ductal hyperplasia upstaging to malignancy: evidence for a watch and wait strategy of a high-risk lesion. Ann Surg Oncol. 2020;27:4622–7 (Springer Science and Business Media Deutschland GmbH).

Article  Google Scholar 

Amin AL, Winblad OD, Zupon A, Fang F, Tawfik O, Wick J, et al. Atypical ductal hyperplasia on percutaneous breast biopsy: Scoring system to identify the lowest risk for upgrade. Arch Breast Cancer. 2022;9(2):144–51. https://doi.org/10.32768/abc.202292144-151.

Chen LY, Hu J, Tsang JYS, Lee MA, Ni YB, Chan SK, et al. Diagnostic upgrade of atypical ductal hyperplasia of the breast based on evaluation of histopathological features and calcification on core needle biopsy. Histopathology. 2019;75:320–8 (Blackwell Publishing Ltd).

Article  PubMed  Google Scholar 

Zhang C, Wang EY, Liu F, RuhulQuddus M, James Sung C. Type of architecture, presence of punctate necrosis, and extent of involvement in atypical ductal hyperplasia can predict the diagnosis of breast carcinoma on excision: a clinicopathologic study of 143 cases. Int J Surg Pathol. 2021;29:716–21 (SAGE Publications Inc.).

Article  CAS  PubMed  Google Scholar 

Karwowski P, Lumley D, Stokes D, Pavlica M, Edsall B, Fu S, et al. Atypical ductal hyperplasia on core needle biopsy: outcomes of 200 consecutive cases from a high-volume program. Breast J. 2021:27:287–90. https://doi.org/10.1111/tbj.14170.

Muller KE, Roberts E, Zhao L, Jorns JM. Isolated atypical lobular hyperplasia diagnosed on breast biopsy low upgrade rate on subsequent excision with long-term follow-up. Arch Pathol Lab Med. 2018;142:391–5 (College of American Pathologists).

Article  PubMed  Google Scholar 

Schiaffino S, Cozzi A, Sardanelli F. An update on the management of breast atypical ductal hyperplasia. Br J Radiol. 2020;93:20200117.

Article  PubMed  Google Scholar 

Williams KE, Amin AL, Hill J, Walter C, Inciardi M, Gatewood J, et al. Radiologic and pathologic features associated with upgrade of atypical ductal hyperplasia at surgical excision. Acad Radiol. 2019;26:893–9.

Article  PubMed  Google Scholar 

Lo Gullo R, Vincenti K, Rossi Saccarelli C, Gibbs P, Fox MJ, Daimiel I, et al. Diagnostic value of radiomics and machine learning with dynamic contrast-enhanced magnetic resonance imaging for patients with atypical ductal hyperplasia in predicting malignant upgrade. Breast Cancer Res Treat. 2021;187:535–45 (Springer).

Article  PubMed  PubMed Central  Google Scholar 

Speer ME, Huang ML, Dogan BE, Adrada BE, Candelaria RP, Hess KR, et al. High risk breast lesions identified on MRI-guided vacuum-assisted needle biopsy: outcome of surgical excision and imaging follow-up. Br J Radiol. 2018;91:20180300. https://doi.org/10.1259/bjr.20180300.

Weiss JB, Woo SD, Forte DM, Sheldon RR, Childers CK, Sohn VY. Is bigger better? Twenty-year institutional experience of atypical ductal hyperplasia discovered by core needle biopsy. Am J Surg. 2019;217(5):906–9. https://doi.org/10.1016/j.amjsurg.2019.01.028.

Cullinane C, Byrne J, Kelly L, Sullivan MO, Corrigan MA, Redmond HP. The positive predictive value of vacuum assisted biopsy (VAB) in predicting final histological diagnosis for breast lesions of uncertain malignancy (B3 lesions): a systematic review & meta-analysis. Eu J Surg Oncol. 2022;48(7):1464–74. https://doi.org/10.1016/j.ejso.2022.04.005.

Amitai Y, Menes TS, Scaranelo A, Fleming R, Kulkarni S, Ghai S, et al. Lobular neoplasia occult on conventional imaging and diagnosed on MRI-guided biopsy: can we estimate upgrade on surgical pathology? Breast Cancer Res Treat. 2020;184:881–90 (Springer).

Article  CAS  PubMed  Google Scholar 

Schmidt H, Arditi B, Wooster M, Weltz C, Margolies L, Bleiweiss I, et al. Observation versus excision of lobular neoplasia on core needle biopsy of the breast. Breast Cancer Res Treat. 2018;168:649–54 (Springer New York LLC).

Article  PubMed  Google Scholar 

Genco IS, Tugertimur B, Chang Q, Cassell L, Hajiyeva S. Outcomes of classic lobular neoplasia diagnosed on breast core needle biopsy: a retrospective multi-center study. Virchows Archiv. 2020;476:209–17 (Springer).

Article  PubMed  Google Scholar 

Linsk A, Mehta TS, Dialani V, Brook A, Chadashvili T, Houlihan MJ, et al. Surgical upgrade rate of breast atypia to malignancy: an academic center’s experience and validation of a predictive model. Br J. 2018;24:115–9 (Blackwell Publishing Inc.).

Google Scholar 

Pride RM, Jimenez RE, Hoskin TL, Degnim AC, Hieken TJ. Upgrade at excisional biopsy after a core needle biopsy diagnosis of classic lobular carcinoma in situ. Surgery (United States). 2021;169:644–8 (Mosby Inc.).

Google Scholar 

Lee J, Ku GY, Lee H, Park HS, Ku JS, Kim JY, et al. Lobular carcinoma in situ during preoperative biopsy and the rate of upgrade. Cancer Res Treat. 2022;54:1074–80 (Korean Cancer Association).

Article  PubMed  Google Scholar 

Elfgen C, Tausch C, Rodewald AK, Güth U, Rageth C, Bjelic-Radisic V, et al. Factors indicating surgical excision in classical type of lobular neoplasia of the breast. Breast Care. 2022;17:121–9 (Basel8. S. Karger AG).

Article  PubMed  Google Scholar 

Catanzariti F, Avendano D, Cicero G, Garza-Montemayor M, Sofia C, Venanzi Rullo E, et al. High-risk lesions of the breast: concurrent diagnostic tools and management recommendations. Insights Imaging. 2021;12(1):63. https://doi.org/10.1186/s13244-021-01005-6.

Kilgore LJ, Yi M, Bevers T, Coyne R, Lazzaro M, Lane D, et al. Risk of breast cancer in selected women with atypical ductal hyperplasia who do not undergo surgical excision. Ann Surg. 2022;276:e932–6.

Article  PubMed  Google Scholar 

Matar R, Sevilimedu V, Park A, King TA, Pilewskie M. Comparison of outcomes for classic-type lobular carcinoma in situ managed with surgical excision after core biopsy versus observation. Ann Surg Oncol. 2022;29:1670–9.

Article  PubMed  Google Scholar 

Cen C, Chun J, Schnabel F. Management of women at increased risk for breast cancer secondary to high-risk proliferative lesions and family history of the disease. Breast J. 2020;26:1543–8 (Blackwell Publishing Inc.).

Article  PubMed  Google Scholar 

Laws A, Mulvey TM. Implementation of a high-risk breast clinic for comprehensive care of women with elevated breast cancer risk identified by risk assessment models in the community. JCO Oncol Pract. 2021;17:e217-25.

Article  PubMed  Google Scholar 

Brewster AM, Thomas P, Brown P, Coyne R, Yan Y, Checka C, et al. A system-level approach to improve the uptake of antiestrogen preventive therapy among women with atypical hyperplasia and lobular cancer in situ. Cancer Prev Res Am. 2018;11:295–302 (American Association for Cancer Research Inc.).

Article  CAS  Google Scholar 

Roche CA, Tang R, Coopey SB, Hughes KS. Chemoprevention acceptance and adherence in women with high-risk breast lesions. Breast J. 2019;25:190–5 (Blackwell Publishing Inc.).

Article  PubMed  Google Scholar 

Bychkovsky B, Laws A, Katlin F, Hans M, KnustGraichen M, Pace LE, et al. Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen. Breast Cancer Res Treat. 2022;193:417–27 (Springer).

Article  PubMed  PubMed Central  Google Scholar 

Decensi A, Puntoni M, Guerrieri-Gonzaga A, Caviglia S, Avino F, Cortesi L, et al. Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. J Clin Oncol. 2019;37:1629–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Valero MG, Zabor EC, Park A, Gilbert E, Newman A, King TA, et al. The Tyrer-Cuzick model inaccurately predicts invasive breast cancer r